First-Line Treatment of HER2-Positive Metastatic Breast Cancer With Dual Blockade Including Biosimilar Trastuzumab (SB3): Population-Based Real-World Data From the DBCG

PURPOSE: Dual blockade with trastuzumab and pertuzumab in combination with chemotherapy is the recommended first-line therapy for human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC). The purpose of this retrospective study is to examine the clinical outcomes of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Celik, Alan, Berg, Tobias, Nielsen, Lise Birk, Jensen, Maj-Britt, Ejlertsen, Bent, Knoop, Ann, Andersson, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8961366/
https://www.ncbi.nlm.nih.gov/pubmed/35359608
http://dx.doi.org/10.1177/11782234221086992

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8961366/
https://www.ncbi.nlm.nih.gov/pubmed/35359608
http://dx.doi.org/10.1177/11782234221086992

Ejemplares similares